Rosen Law Firm Urges Mereo BioPharma ADS Investors to Act by April 6 Lead Plaintiff Deadline

Reuters03-05 09:33
Rosen Law Firm Urges Mereo BioPharma ADS Investors to Act by April 6 Lead Plaintiff Deadline

Rosen Law Firm is urging investors who bought Mereo BioPharma Group plc American Depositary Shares between June 5, 2023 and Dec. 26, 2025 to seek counsel ahead of an April 6, 2026 deadline to seek lead plaintiff status in a securities class action. The lawsuit alleges the company and others made misleading statements about expectations for Phase 3 ORBIT and COSMIC studies of setrusumab in osteogenesis imperfecta, and that both trials failed to meet their primary endpoints, allegedly inflating the share price and causing investor losses when the results became known.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603042033PRIMZONEFULLFEED9666138) on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment